This article is more than 5 years old. Information may no longer be current.

Aerie reports quarterly loss

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Aerie Pharmaceuticals posted a GAAP net loss of $40.7 million, or $1.05 per share, in the first quarter of 2018 compared with a GAAP net loss of $25.8 million, or $0.76 per share, in 2017’s first quarter.

Operating expenses increased in the quarter from $25.4 million in 2017 to $40.8 million in 2018, which reflects increased activities to expand the company’s employee base to support operation growth and activities associated with efforts to commercialize Rhopressa (netarsudil ophthalmic solution 0.02%), according to a press release.

Aerie had cash, cash equivalents and investments of $334 million as of March 31.